The Birmingham ECMC and Cancer Research UK Birmingham Centre together provide the infrastructure and governance to align and integrate our academic and clinical resources, accelerating the translational outputs of three complementary research strengths, namely in immunology, genomics and virology.
Focusing predominantly on established clinical strengths in colorectal cancer, head and neck cancer, lung cancer, and haematological malignancies (key contacts for clinical groupings listed in key themes below), the Birmingham ECMC drives forward the translation of fundamental research.
Our principal focus is on innovatively-designed Phase 1/2 trials, recruiting stratified patient cohorts, seeking robust therapeutic signals capable of transforming patient outcomes, and also integration with optimised surgical approaches. This synergises with Cancer Research UK’s Clinical Trials Unit (CRCTU’s) expertise and strategic aims, including efficient trial design, such as adaptive/multi-arm/multi-stage and novel window-of-opportunity studies.
We are strategically linked with the West Midlands Regional Genetics Laboratory which is one of CRUK's Technology Hubs in Stratified Medicine Programme and of strategic importance in the context of linking translation to potential delivery with respect to genetic biomarkers.